Of 93 consecutively treated patients with acute myeloid leukemia 36 (39%) achieved complete remission (CR). Thirty-five patients were randomized to receive either maintenance chemotherapy alone (C) or a combination of active nonspecific immunotherapy with Corynebacterium parvum and chemotherapy (C + I). Maintenance therapy was given monthly for 1 year or until relapse. The median survival time was 21 months for patients treated with chemotherapy alone, compared with 30 months for patients treated with chemotherapy and immunotherapy. The median remission duration was 15 months for patients treated with chemotherapy, compared with 18 months for chemotherapy and immunotherapy group. While no statistically significant difference in remission duration or survival time could be attributed to the use of immune stimulation, a plateau of 40% long-term time survivors was defined in the chemotherapy and immunotherapy group. Age and sex were found to be the major prognostic factors for achievement of CR. No difference was found in remission duration or survival between the two different induction schedules. Neither did the morphological subtype of AML (FAB classification) or the leukocyte count at diagnosis correlate with remission rate or survival.

Adjuvants, Immunologic↗

PubMed1982

Correlation of Electrophysiology and morphology in myocardial sarcoidosis. A case report.

A 44-year-old man with systemic sarcoidosis for 11 years developed myocardial sarcoidosis with left bundle branch block and recurrent ventricular tachycardia prior to death. Autopsy showed granulomas and fibrosis in the myocardium including the left ventricular free wall, septum and His bundle, particular the left bundle branch. This is in accordance with the ECG findings.

Adult↗

PubMed1980

Effects of long-term high-dose labetalol on blood pressure in patients with severe hypertension resistant to previous therapy.

Explore the source record for details and available documents.

Blood Pressure↗

PubMed1980

The effect of exercise on intra-arterial blood pressure and pulse rate before and during long-term high-dose treatment with labetalol in patients with severe, therapy-resistant hypertension.

Intra-arterial blood pressure (BP) and pulse rate were measured before, during and after submaximum exercise in 15 patients with severe, therapy-resistant hypertension. Measurements were performed at the start of treatment with labetalol and were repeated after three and six months of therapy. Thirteen patients were examined twice and 11 patients three times. The average daily dose of labetalol was 2185 mg (range 600-4200 mg) after three months and 3036 mg (range 800-6000 mg) after six months. At rest, there were no significant changes in BP or pulse rate in the three investigations. During exercise, a significantly lower increase in both systolic and diastolic BP-but not in pulse rate-was found six months after starting treatment with labetalol. After six months of treatment with labetalol a correlation was found between the labetalol dose and changes in BP.

Blood Pressure↗